Clinical Trials

Inclusion Criteria:

• 18 years of age orolder
• Histologic proof of malignancy, including metastatic melanoma and metastatic non-smallcell lungcancer
• CT or PET/CT evidence of measurable lymph node involvement, 2-4cm in size in the longest diameter
• Recommendation by the treating provider to initiate therapy with a commercially available, FDA approved, anti-PD-1-based therapy or anti-PD-L1therapy
• The ability and willingness to sign an informed consent

Exclusion Criteria:

• Pregnancy or lactation (forfemales); pregnancy test will have been completed as per standard of care prior to treatment and does not need to be repeated for this study
• Inability on the part of the patient to understand the informed consent or be compliant withthe protocol
• Previous adjuvant immunotherapy with immune checkpointinhibitor(s)
• Previous systemic immune checkpoint inhibitor(s)therapy
• Other active malignancies within 3years
• Any conditions, which in the opinion of the patient’s treating oncologist, or the provider performing the biopsy procedure, would make participation in this protocol unreasonably hazardous for the patient (including a history of bleeding disorder and a serious or life- threatening allergic reaction to such local anesthetics as lidocaine orxylocaine)